v3.26.3
Segment Information
 9 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
Segment Information Segment Information
We operate as a single reportable segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide. A global research and development organization and a supply chain organization are responsible for the discovery, development, manufacturing, and supply of our products. Our commercial organizations market, distribute, and sell the products. The business is also supported by global corporate staff functions. Our determination that we operate as a single segment is consistent with the nature of our operations and the financial information regularly reviewed by the chief executive officer, in his capacity as the chief operating decision maker (CODM), for the purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods.
Our purpose is to unite caring with discovery to create medicines that make life better for people around the world. Our long-term success is significantly dependent on our ability to research and develop innovative medicines. The CODM uses consolidated net income to assess performance of our company, ensuring that we are investing in future research and development while efficiently delivering products to patients. The CODM allocates research and development resources based upon several factors, including the likelihood of technical success, unmet medical needs, and the viability of commercial success. A significant component of the CODM’s decision-making process is to ensure a balanced investment in our research and development portfolio to drive near-term success and sustain for the long-term.
The following table summarizes information for our single reportable segment, including significant segment expenses:
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Revenue$24,397 $17,601 $67,170 $45,887 
Less:
Cost of sales3,933 3,008 10,778 7,680 
Early-stage research and development(1)
1,663 1,250 4,379 3,396 
Late-stage research and development(1)
2,584 2,216 7,197 6,140 
Marketing, selling, and administrative3,125 2,741 9,489 7,963 
Acquired in-process research and development4,181 656 7,541 2,381 
Other segment items(2)
2,460 2,148 6,844 4,325 
Net income$6,451 $5,583 $20,942 $14,002 
Interest expense$378 $180 $1,055 $672 
Expenditures for long-lived assets(3)
3,639 2,320 8,983 5,821 
(1) Early-stage research and development primarily includes costs incurred from discovery through Phase 2 clinical trials. Late-stage research and development primarily includes costs incurred from Phase 3 clinical trials.
(2) Other segment items primarily include income taxes.
(3) Includes expenditures for property and equipment and computer software costs.